Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sonelokimab (M1095), is MoonLake’s investigational Nanobody® designed to treat inflammatory disease by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
Brand Name : M1095
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
